RANBP2 like and GRIP domain containing 5Genealiases: BS-63 · BS63 · HEL161 · RGP5
Q-omics provides the consensus-scored RGPD5 profile across patient tissues and cancer cell-line models. RGPD5 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RGPD5 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, RGPD5 RNA expression shows 13,033 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, THCA, and THYM as cancer lineages where RGPD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RGPD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RGPD5 survival associations across molecular data types. RGPD5 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RGPD5 RNA expression–survival associations across cancer types. High RGPD5 expression shows unfavorable associations in STAD, ACC, CESC and LUAD, but favorable associations in UCS and PAAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for RGPD5 RNA expression.
This table summarizes RGPD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RGPD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RGPD5 shows lower tumor expression in THCA and higher tumor expression in HNSC. The THCA box plot shows higher RGPD5 RNA expression in normal versus tumor tissue (log2 FC = −0.004, t-test p = .001).
This table shows molecular features associated with RGPD5 in patient tissues and cancer cell lines. In patient samples, RGPD5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RGPD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and OESOPHAGUS.
